Essential Hypertension (Adjunctive)
Investigational adjunctive use; mechanism includes mild diuresis from blood-volume removal and hirudin-mediated vascular endothelial effects. Not a substitute for pharmacotherapy.
Patient Summary
- Is this FDA-cleared for this use?
- Not FDA-cleared for hypertension. FDA cleared medicinal leeches only for venous congestion in microsurgical reconstruction (K040187, 2004). Use for high blood pressure is investigational.
- What evidence exists?
- Tier C (investigational). Small case series suggest modest, short-term systolic blood pressure reductions (about 8 to 12 mmHg) after 2 to 3 sessions, with no controlled trials and no long-term outcome data on heart attack or stroke. Evidence-based first-line therapy is lifestyle change (sodium reduction, weight loss, exercise, alcohol moderation) plus proven antihypertensive medications (thiazides, ACE inhibitors / ARBs, calcium channel blockers) — these have decades of cardiovascular-outcome data behind them.
- Main risks
- Bleeding from bite sites for 6 to 24 hours after detachment
- Bruising and tenderness over the placement areas for 5 to 10 days
- Lightheadedness or low blood pressure on standing, especially if antihypertensive medications are not adjusted
- Local skin infection or, rarely, Aeromonas infection
- Allergic reaction to leech saliva (uncommon)
- Anemia from cumulative blood loss across multiple sessions
- False reassurance leading to skipping or delaying evidence-based pharmacotherapy — with risk of heart attack, stroke, kidney disease
- Who should not consider this
- Patients with severe uncontrolled hypertension (BP over 180/110)
- Patients within 6 months of a heart attack, stroke, or transient ischemic attack
- Patients with symptomatic orthostatic hypotension or frequent falls
- Patients on anticoagulants (warfarin INR over 2.0, DOACs, heparin)
- Patients with hemophilia, severe anemia (Hb under 10 g/dL), or active infection
- Patients using this as a replacement for prescribed antihypertensives
- What to ask your clinician
- What is my cardiovascular risk score, and what is my blood-pressure target?
- Have I tried lifestyle modification (DASH diet, sodium under 1500 mg/day, regular aerobic exercise, weight loss if applicable)?
- What antihypertensive medications have I tried, and at what doses?
- Will my prescriber be involved in dose adjustment if I pursue complementary therapy?
- How will my blood pressure be monitored during and after treatment (home BP log)?
- What is the practitioner's experience and Aeromonas-prevention plan?
- What is the realistic effect size and duration?
- When to seek urgent care
- Chest pain, pressure, or shortness of breath (possible heart attack — call 911)
- Sudden weakness on one side, slurred speech, facial droop, or vision loss (possible stroke — call 911)
- Blood pressure over 180/120 with headache, vision change, or chest pain (hypertensive emergency)
- Severe lightheadedness, fainting, or a fall
- Bleeding from a bite site lasting more than 24 to 48 hours
- Fever above 38.0 C / 100.4 F, spreading redness, or pus
- Hives, throat tightness, or breathing difficulty
What this does NOT mean
- This is not FDA-cleared for hypertension.
- Small short-term BP reductions in case series do NOT prove reduction of heart attack, stroke, or kidney damage.
- Mechanism rationale (volume reduction, endothelial effects) does NOT establish clinical efficacy at scale.
- Leech therapy is NEVER a substitute for evidence-based antihypertensive medications when indicated.
- Any antihypertensive medication changes require your prescriber's involvement, not self-titration.
Safety cross-references
Clinical Profile
- Category
- cardiovascular
- ICD-10
- I10
- Safety tier
- medium
Evidence Summary
Historical use of bloodletting for hypertension dates to antiquity. No controlled clinical trial or case series of leech therapy for essential or resistant hypertension has been published; human clinical evidence is absent and any use is investigational and mechanistic only. The proposed mechanism combines a temporary blood-volume reduction (analogous to therapeutic phlebotomy in polycythemia) with hypothesized endothelial effects from absorbed salivary peptides, but neither has been demonstrated to lower blood pressure in patients. ASH position: leech therapy is NEVER a replacement for evidence-based antihypertensive pharmacotherapy and should not be used as a substitute for it. It has no established role in the management of hypertension and should only be considered, if at all, within a research protocol under cardiology supervision.
Treatment specifics
How many leeches, where they are placed, how long a session lasts, and whether to repeat are clinical decisions made by a qualified provider under institutional protocol — not something to self-administer. Discuss the specifics with a clinician experienced in medicinal leech therapy. (Clinicians: switch the audience selector in the top bar to “Clinician” to view protocol detail.)
Key Trials
- Ashraf S et al. (2014), n=44
- Khalil M et al. (2019), n=22
Contraindications
- Active anticoagulant therapy (warfarin INR >2.0, DOACs, heparin)
- Hemophilia or other bleeding disorder
- Severe anemia (Hb <10 g/dL)
- Active bacteremia or sepsis
- Known hypersensitivity to leech salivary proteins
- Pregnancy (relative — first/third trimester)
- Immunocompromised state with severe neutropenia
- Uncontrolled severe hypertension (BP >180/110)
- Recent (<6 months) myocardial infarction or stroke
- Symptomatic orthostatic hypotension
Related ASH Compounds
Leech-derived molecules implicated in this condition, each profiled in the ASH compound registry:
Related Conditions
Atrial Fibrillation (Adjunctive Investigational)
Highly investigational adjunct for paroxysmal atrial fibrillation; no controlled trials; conventional anticoagulation and rate/rhythm control remain primary.
Congestive Heart Failure (Compensated, Investigational Adjunct)
Investigational adjunct in compensated NYHA II heart failure; no RCT support; guideline-directed medical therapy remains primary.
Peripheral Artery Disease (Claudication, Investigational)
Highly investigational adjunct for intermittent claudication; ABI must be assessed first; critical limb ischemia is an absolute contraindication.